SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) from its SEC filings: 2025 revenue $719.0 million (+9% vs the year before), net margin -5%, free cash flow $46.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $719.0 million |
| Revenue growth | +9% |
| Net income | -$38.6 million |
| Net margin | -5.4% |
| Free cash flow | $46.0 million |
| Diluted EPS | $-0.68 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +32% |
| Cash | $180.0 million |
| Long-term debt | $0 |
| Share count, 1 year | +4% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.